Literature DB >> 7883446

Regulatory effect of anti-interleukin-5 monoclonal antibody on intestinal worm burden in a primary infection with strongyloides venezuelensis in mice.

M Korenaga1, Y Hitoshi, K Takatsu, I Tada.   

Abstract

The intestinal worm burden in Strongyloides venezuelensis-infected mice was influenced by treatment with anti-interleukin-5 (IL-5) monoclonal antibody (NC17) when NC17 was given to mice 3-7 days before infection. The present study has examined the involvement of IL-5 in susceptibility at different in the development of the parasite in the host. The results show that the number of tissue-migrating larvae recovered from the lungs in a primary infection was not affected by anti-IL-5 monoclonal antibody treatment, whereas intestinal worm counts increased in mice treated with 0.25-1 mg of NC17. In mice treated with 0.1 mg of NC17, adult worm recovery was not significantly different from non-treated controls. Peripheral and tissue eosinophilia were not observed in the early phase of infection (days 4-8). Six days after transfer of lung-stage larvae to NC17-treated mice, adult worm recovery was higher than that of control mice. These results suggest that non-eosinophil response(s), which were dependent on IL-5, were involved in the initial establishment of the intestinal stage of S. venezuelensis in mice. We discuss the mechanisms that control the susceptibility to the parasite from the viewpoint of host defence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7883446     DOI: 10.1016/0020-7519(94)90159-7

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  9 in total

1.  Role of eosinophils and neutrophils in innate and adaptive protective immunity to larval strongyloides stercoralis in mice.

Authors:  Ann Marie Galioto; Jessica A Hess; Thomas J Nolan; Gerhard A Schad; James J Lee; David Abraham
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

2.  Drastic reduction of a filarial infection in eosinophilic interleukin-5 transgenic mice.

Authors:  C Martin; L Le Goff; M N Ungeheuer; P N Vuong; O Bain
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

3.  Eosinophils can function as antigen-presenting cells to induce primary and secondary immune responses to Strongyloides stercoralis.

Authors:  Udaikumar M Padigel; James J Lee; Thomas J Nolan; Gerhard A Schad; David Abraham
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Regulation of primary Strongyloides ratti infections in mice: a role for interleukin-5.

Authors:  K S Ovington; K McKie; K I Matthaei; I G Young; C A Behm
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

5.  Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines.

Authors:  David B Corry; Attila Kiss; Li-Zhen Song; Ling Song; Jie Xu; Seung-Hyo Lee; Zena Werb; Farrah Kheradmand
Journal:  FASEB J       Date:  2004-04-01       Impact factor: 5.191

6.  Eosinophils act as antigen-presenting cells to induce immunity to Strongyloides stercoralis in mice.

Authors:  Udaikumar M Padigel; Jessica A Hess; James J Lee; James B Lok; Thomas J Nolan; Gerhard A Schad; David Abraham
Journal:  J Infect Dis       Date:  2007-12-15       Impact factor: 5.226

Review 7.  Eosinophils and helminth infection: protective or pathogenic?

Authors:  E Mitre; A D Klion
Journal:  Semin Immunopathol       Date:  2021-06-24       Impact factor: 9.623

Review 8.  Importance of Both Innate Immunity and Acquired Immunity for Rapid Expulsion of S. venezuelensis.

Authors:  Koubun Yasuda; Makoto Matsumoto; Kenji Nakanishi
Journal:  Front Immunol       Date:  2014-03-19       Impact factor: 7.561

9.  Eosinophils Control Liver Damage by Modulating Immune Responses Against Fasciola hepatica.

Authors:  Sofía Frigerio; Valeria da Costa; Monique Costa; María Florencia Festari; Mercedes Landeira; Santiago A Rodríguez-Zraquia; Steffen Härtel; Jorge Toledo; Teresa Freire
Journal:  Front Immunol       Date:  2020-09-18       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.